In:
Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 27, No. 1 ( 2020-02-18), p. 23-31
Abstract:
Orphan drug products (e.g. drugs and biologics) in the United States are those that treat people with rare chronic diseases, often cancer or metabolic disease. The rare disease condition
being treated by these orphan drugs must serve a patient population of less than 200,000 people in the U.S. in order to earn the orphan drug product title. Just as the disease conditions are seen as
“orphans,” so, we assert is the thermochemical understanding of the drugs themselves in terms of the chemical structures that define those drugs. This article illustrates this orphan thermochemical
status for a recent series of orphan drugs.
Type of Medium:
Online Resource
ISSN:
0929-8673
DOI:
10.2174/0929867325666181101120058
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2020
SSG:
15,3
